Skip to main content
. 2020 Oct 8;12(10):2884. doi: 10.3390/cancers12102884

Figure 2.

Figure 2

The chemotherapy-resistant cell lines Cl66-Doxorubicin (Cl66-Dox), and Cl66-Paclitaxel (Cl66-Pac). supernatants enhanced neutrophil survival. (A) Bar graph showing higher viability of differentiated MPRO in the supernatant of chemotherapy-resistant cell lines (Cl66-Dox and Cl66-Pac) in comparison with thee supernatant of parental Cl66 cells. Similarly, bar graphs showing an increase in the survival of differentiated neutrophils with an increase in the gradient of the supernatant of Cl66, Cl66-Dox, and Cl66-Pac cells. (B) Bar graph showing higher viability of undifferentiated MPRO in the supernatant of chemotherapy-resistant cell lines (Cl66-Dox and Cl66-Pac) in comparison with supernatant of parental Cl66 cells. Similarly, bar graphs show an increase in the survival of undifferentiated neutrophils with an increase in the gradient of the supernatant of Cl66, Cl66-Dox, and Cl66-Pac cells. The values are shown as mean ± SEM. The data are representative of three independent experiments performed in triplicate with similar results. Unpaired Student’s t-test; * p < 0.05; ** p < 0.01; *** for p ≤ 0.001; **** for p ≤ 0.0001.